Das in der Schweiz ansässige Team von Pharmaexperten von Refarmed betreut rund 300 Kunden in Europa, Asien und Amerika. Refarmed erwirtschaftet einen Nettoumsatz von über CHF 60 Mio. bei solider Rentabilität und Kapitalrendite.
Durch die Übernahme der Refarmed Group erhält die DKSH Business Unit Performance Materials, der weltweit führende Distributor für die Synthese und Formulierung innovativer pharmazeutischer Inhaltsstoffe mit einer enormen und ständig wachsenden globalen geografischen Reichweite, ein einzigartig positioniertes Unternehmen, das Mehrwertprodukte und -dienstleistungen für Kunden in der Pharmaindustrie in ganz Europa, im asiatisch-pazifischen Raum und in Amerika. DKSH Switzerland Ltd wird das Unternehmen übernehmen und die Refarmed Group vollständig in ihre bestehenden Aktivitäten integrieren.
Team von Homburger
Das Homburger Team bestand aus Partner Frank Gerhard, den Associates Anna Peter und Timo Hasler, Junior Associate Alexander Cochardt (alle Corporate / M&A) sowie Partner Reto Heuberger und Associate Laetitia Fracheboud (beide Tax).
Information von DKSH über die Transaktion
DKSH informiert wie folgt über die Transaktion:
Through the acquisition of Refarmed Group, DKSH Performance Materials obtains a uniquely positioned business which provides value-added products and services for customers in the pharma industry across Europe, Asia Pacific, and the Americas.
Refarmed Group provides Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for generic drug manufacturers. This includes the sourcing of the ingredients as well as providing technical and regulatory support. Headquartered in Switzerland, Refarmed’s team of pharmaceutical experts serves approximately 300 customers across Europe, Asia, and the Americas.
Refarmed generates net sales of over CHF 60 million at sound profitability and return on capital. DKSH will acquire the business and will fully integrate the company into its existing operations.
Dr. Giuseppe Nonni, President at Refarmed, commented: „We have successfully serviced our customers for almost 40 years. In DKSH, we have found an experienced and trusted partner and we look forward to leveraging our expertise through their international reach and market expertise.“
Thomas Sul and Natale Capri, Co-Heads Business Unit Performance Materials at DKSH, jointly added: “We are excited to strengthen our capabilities in Life Sciences by teaming up with a trusted player with strong expertise. Refarmed’s products and services complement our existing portfolio and increases our access Pharma industries. We welcome all Refarmed employees and look forward to continuing to grow the business together with them.”
Über Refarmed
Die Refarmed stellt sich wie folgt dar auf der Website:
Refarmed Chemicals was originally established in the early 1970’s in central Switzerland under the name of Refarmed Research Pharmaceutique and for more than 40 years has been committed to employing innovation across the global generic pharmaceutical industry.
From these early roots, Refarmed has grown into a privately held multi-service, customer-driven active ingredient distributing company dedicated to providing a high level of service.
Through its stakeholding system, Refarmed is fully integrated in the pharmaceutical industry from APIs to FDFs.
Refarmed maintains a historical presence in the clinical and biological sector that perfectly complements its skill and relevant expertise.
